Long-term Efficacy of TNF-alpha Inhibitors on Persistent Uveitic Macular Edema: A Swiss Multicenter Cohort Study.
Details
Serval ID
serval:BIB_3742A8D722D8
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Long-term Efficacy of TNF-alpha Inhibitors on Persistent Uveitic Macular Edema: A Swiss Multicenter Cohort Study.
Journal
Ocular immunology and inflammation
ISSN
1744-5078 (Electronic)
ISSN-L
0927-3948
Publication state
Published
Issued date
07/2023
Peer-reviewed
Oui
Volume
31
Number
5
Pages
981-988
Language
english
Notes
Publication types: Multicenter Study ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
To assess the efficacy of tumor necrosis factor-alpha inhibitors (TNFi) on uveitic macular edema (ME) unresponsive to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).
This multicenter retrospective study included patients with uveitic ME persisting despite csDMARDs. The effect of an additional TNFi on central retinal thickness (CRT), best corrected visual acuity (BCVA) and corticosteroid need was evaluated.
Thirty-five eyes (26 patients, mean age 42.9 ± 15.2 years) were included. CRT decreased from 425 ± 137 µm to 294 ± 66 µm (p < .001) and 280 ± 48 µm (p < .001) at 1 and 4 years of follow-up, respectively. BCVA improved from 0.28 ± 0.22 to 0.21 ± 0.48 (1 year, p = .013) and 0.08 ± 0.13 logMAR (4 years, p = .002). The proportion of patients requiring systemic corticosteroids decreased from 88.5% to 34.8% (1 year) and 15.4% (4 years).
The addition of a TNFi resulted in an improvement of CRT and BCVA for up to 4 years in uveitic ME but rescue treatments were needed for some patients.
This multicenter retrospective study included patients with uveitic ME persisting despite csDMARDs. The effect of an additional TNFi on central retinal thickness (CRT), best corrected visual acuity (BCVA) and corticosteroid need was evaluated.
Thirty-five eyes (26 patients, mean age 42.9 ± 15.2 years) were included. CRT decreased from 425 ± 137 µm to 294 ± 66 µm (p < .001) and 280 ± 48 µm (p < .001) at 1 and 4 years of follow-up, respectively. BCVA improved from 0.28 ± 0.22 to 0.21 ± 0.48 (1 year, p = .013) and 0.08 ± 0.13 logMAR (4 years, p = .002). The proportion of patients requiring systemic corticosteroids decreased from 88.5% to 34.8% (1 year) and 15.4% (4 years).
The addition of a TNFi resulted in an improvement of CRT and BCVA for up to 4 years in uveitic ME but rescue treatments were needed for some patients.
Keywords
Humans, Adult, Middle Aged, Macular Edema/diagnosis, Macular Edema/drug therapy, Macular Edema/etiology, Tumor Necrosis Factor-alpha/therapeutic use, Tumor Necrosis Factor Inhibitors/therapeutic use, Retrospective Studies, Switzerland, Treatment Outcome, Follow-Up Studies, Intravitreal Injections, Uveitis/complications, Uveitis/diagnosis, Uveitis/drug therapy, Tomography, Optical Coherence, Adalimumab, TNF-alpha inhibitors, infliximab, macular edema, uveitis
Pubmed
Web of science
Create date
24/05/2022 8:58
Last modification date
04/07/2023 6:54
Usage data
